Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
This invention relates to methods for manipulating the immune system using small interfering RNA (siRNA). Potential applications include the development of organ storage/reperfusion solutions and treatments for a broad range of disease indications. More
The present technology describes recombinant poxvirus vectors encoding at least three or more costimulatory molecules and TAAs. More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
Discovery of a promising new class of potent alkyltransferase inactivators, 2-amino-O4-benzylpteridine derivatives More
A novel anti-angiogenic method for treating cancer More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
Our invention relates to a novel anti-cancer therapy involving the silencing of tumour-derived immunosuppressive genes using siRNA. More
A cancer therapy and diagnostic that utilizes a variation of "Boron Neutron Capture Therapy" to deliver intense, short-lived, therapeutic doses of radiation specifically to active tumor sites. More
A new method for enhancing L-ASP activity by combining it with antagonists of asparagine synthetase - such as siRNAs, antisense nucleotides, antibodies or small-molecule inhibitors More
Your selection
Browse By
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us